Evidence map›Paper›PMID 41753261›Full record

ReviewJournal of clinical medicine2026

Modern Personalized Strategies for Breast Cancer Treatment: Bridging Precision Oncology and Psycho-Oncology.

Giuseppe Marano, Ida Paris, Gianandrea Traversi, Osvaldo Mazza, Francesco Pavese, Tatiana D'Angelo, Gianluca Franceschini, Marianna Mazza

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giuseppe MaranoDepartment of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.ORCID 0000-0001-7058-4927
Ida ParisDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0002-7445-3366
Gianandrea TraversiUnit of Medical Genetics, Department of Laboratory Medicine, Ospedale Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.ORCID 0000-0002-6558-2932
Osvaldo MazzaSpine Surgery Department, Bambino Gesù Children's Hospital IRCCS, 00168 Rome, Italy.
Francesco PaveseDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Tatiana D'AngeloDivision of Gynecologic Oncology, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0009-0001-7807-761X
Gianluca FranceschiniBreast Surgery Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0002-2950-3395
Marianna MazzaDepartment of Neuroscience, Head-Neck and Chest, Section of Psychiatry, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy.ORCID 0000-0002-3007-8162

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer represents a paradigmatic model of precision oncology, with treatment strategies increasingly guided by molecular profiling and biomarker-driven targeted therapies. Despite these advances in biological personalization, clinical outcomes remain strongly influenced by psychological and psychiatric factors that are still insufficiently integrated into oncological decision-making. This gap underscores the need for a broader, person-centered model of personalization that extends beyond tumor biology. This narrative review synthesizes current evidence on contemporary personalized strategies in breast cancer management, with a specific focus on the integration of precision oncology and psycho-oncology. A structured literature search was conducted across major biomedical databases to identify studies addressing molecular stratification, targeted treatments, psychiatric comorbidity, psychological profiles, and psycho-oncological interventions relevant to treatment personalization. While molecular classification and biomarker-guided therapies have substantially improved breast cancer outcomes, high rates of depression, anxiety, psychological distress, and maladaptive coping styles are consistently reported across disease stages. These psychological and psychiatric dimensions significantly influence treatment adherence, tolerability, quality of life, and ultimately clinical outcomes. Growing evidence supports the systematic use of psychological screening tools and tailored psycho-oncological interventions, both psychological and pharmacological, as integral components of personalized cancer care. Integrated care models combining oncological and psycho-oncological expertise are associated with improved patient-reported outcomes and may enhance overall therapeutic effectiveness. True personalization in breast cancer treatment extends beyond biological precision and requires the structured integration of psycho-oncological assessment and intervention into routine clinical pathways. Bridging precision oncology and psycho-oncology enables a more comprehensive, patient-centered approach, optimizing adherence, quality of life, and long-term outcomes. Future strategies should prioritize multidisciplinary models of care and the development of integrated clinical frameworks to achieve genuinely personalized breast cancer management.

Indexed as

breast cancermolecular profilingpersonalized treatmentpsychiatric comorbiditypsycho-oncologytargeted therapies

Identifiers

PMID41753261
PMCPMC12941860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.